[Skip to Navigation]
Views 219
Citations 0
Comment & Response
July 27, 2021

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia—Reply

Author Affiliations
  • 1IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy
  • 2Amgen Research, Munich, Germany
  • 3Charité-Universitätsmedizin Berlin, Berlin, Germany
JAMA. 2021;326(4):359-360. doi:10.1001/jama.2021.8154

In Reply We concur with Dr Shibusawa and colleagues that some authors have suggested that the presence of a high percentage of regulatory T cells in peripheral blood was associated with a lower probability of response to blinatumomab.1 However, we are not aware of any study indicating that a high percentage of regulatory T cells can affect the probability of response to chemotherapy. In our randomized clinical trial,2 blinatumomab was superior to chemotherapy for event-free survival in children with relapsed B-ALL. Therefore, the hypothesis raised by Shibusawa and colleagues does not explain the improved outcomes for patients randomized to immunotherapy.